



AQUA BIO TECHNOLOGY ASA

Commercial update Aqua Bio Technology (ABT)

30.4.2021 08:32:57 CEST | Aqua Bio Technology ASA | Non-regulatory press releases

Products series from DCP Dermosciense (DCP)

Seidr and Seidr Cliniq have now passed all safety studies, which means that the Seidr series (39 products in total) will be ready for distribution and sale in q2 2021. See the first pictures from the series in Appendix 1.

Sister brand from Moana Skincare - B Natural

B Natural is based on the same unique ingredients as Moana Skincare and has been created to adapt the product to other markets, expanding the commercial reach of the unique Moana product line. The B Natural series (21 products in total) is ready for distribution and sale in q2 2021. See the first pictures from the series in Appendix 1.

Update on new e-commerce website for ABT

ABT is launching a new e-commerce website in q2 of 2021 containing all ABT skincare products for shareholder and certain customers and will have B2B log in for ABT's distributors

Restorsea's commercialization of ABT's hatching fluid ingredient (Aquabeautine XL)

ABT's US partner Restorsea has [invested large sums](#) for the exclusive right to use ABT's hatching fluid ingredient as the main ingredient in its own and licensed products. As informed [8 of February 2021](#) Hydrafacial officially announced its partnership with Restorsea and launched in Q1 2021 its new Restorsea Lip Fix Kit which is based on ABT's hatching fluid ingredient (Aquabeautine XL).

LifeMD (former Conversion Labs) [presented NavaMD](#) and its cooperation with Restorsea in Q1 2021 and ABT expecting that the NavaMD products [containing Aquabeautine XL](#) will be launched in the near future.

The positive trend from Restorsea's commercialization of ABT's proprietary technology increases the likelihood that ABT will receive additional renewal payment and increased revenue from the sale of ingredients and royalties.

Pre launch of ABT's products

ABT is planning a pre-launch of ABT's products in q2 and shareholders that would like to learn more about the products and participate in the pre-launch should subscribe and register on [ABT's website](#) to receive examples of our new products.

For further information, please contact CEO Espen Kvale, telephone +47 9162 8092.

* * *

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skin care products has been, and will continue to be, an important part of the Company's strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.

This information was considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. The stock exchange

announcement was published by Håvard Lindstrøm, Head of Business Development, on 30 April 2021, at 08.30 CES

Disclosure regulation

This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.

Contacts

- Espen Kvale, CEO, +47 916 28 092, espen.kvale@aquabiotech.no

About Aqua Bio Technology ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on Euronext Expand.

Attachments

- [Download announcement as PDF.pdf](#)
- [ABT stock exchange message appendix 30 April 2021.pdf](#)